https://www.selleckchem.com/pr....oducts/BafilomycinA1
The quantitative data was insufficient to compare attrition rates. The qualitative data identified more reasons why non-commercial RD costs would be lower than commercial RD, timelines would be longer, and attrition rates would be equivalent or higher, though the data does not allow for estimating the magnitude of these effects. Conclusions The quantitative data suggest that costs and timelines per candidate per phase were largely in line with (lower-end estimates of) commercial averages. We were unable to draw conclusio
Like
Comment
Share
